IDM Pharma Inc to revise New Drug Application

Shares of IDM Pharma Inc. (Nasdaq: IDMI) edged up in pre-market trading after the biopharmaceutical company  announced it plans to revise its New Drug Application for Mifamurtide for the treatment of patients with osteosarcoma.

IDM Pharma said it told the U.S. Food and Drug Administration that it intends to take immediate action to supplement data in its current New Drug Application for mifamurtide (L-MTP-PE), formerly known as Junovan, which is being reviewed for the treatment of children and adolescents with non-metastatic osteosarcoma.

Shares of IDM Pharma bumped up 2.71%, or $0.07, to $2.65 in pre-market trading.

For access to the full article, you must be a registered member - it's FREE.

Already a member? Please log in below